Investors
We announced our full year and fourth quarter 2025 results on Wednesday, 4 February.
Press releases
- GSK’s AREXVY associated with reductions in certain RSV-related risks including heart attack, stroke and severe flare-ups of COPD and asthma, real world study shows
- GSK awards $2M in COiMMUNITY Initiative grants to help close vaccination gaps, commits $3M for 2026
- GSK announces recipients of Linked by Lupus: Optimal Care Initiative grants nearing $1 million

GSK Global links
Visit our Global site for additional features








